Will a malaria vaccine be commercially available by 2013
Background: A vaccine against malaria, which kills more than one million people every year, could be available within five years after extensive trials have shown that it provides significant protection for infants and young children. The vaccine, known only by its codename RTS,S, is the most promising to emerge from 20 years of research and has already demonstrated its efficacy in adults and babies in the Gambia and Mozambique.
The latest trials, in Kenya and Tanzania, have shown for the first time that the vaccine can be administered as part of the standard immunisation programme, without interfering with vaccines against diphtheria, tetanus, whooping cough and meningitis, and still provide protection. This will make delivering it much easier and less costly across Africa and has boosted researchers' hopes of developing an effective weapon against one of the world's worst killer diseases. A final trial involving thousands of children across Africa is planned for next year, if regulatory approval can be obtained.
About 500 million episodes of malaria occur every year, mostly in the developing world. The disease is caused by a parasite transmitted by the female anopheles mosquito and is the leading killer of children under the age of five in sub-Saharan Africa. In the Tanzanian trial, the vaccine reduced infection with malaria over six months by up to 65 per cent in babies under one, who are most vulnerable to disease. A total of 340 infants were included who each received three doses at eight, 12 and 16 weeks. In a separate trial involving almost 900 older children in Kenya and Tanzania, aged five to 17 months, a slightly different version of the same vaccine reduced cases of malaria requiring hospital treatment by 53 per cent. The results were presented yesterday at the annual meeting of the American Society for Tropical Medicine and Hygiene in New Orleans and published in The New England Journal of Medicine.
Read the full The Independent article here.
The latest trials, in Kenya and Tanzania, have shown for the first time that the vaccine can be administered as part of the standard immunisation programme, without interfering with vaccines against diphtheria, tetanus, whooping cough and meningitis, and still provide protection. This will make delivering it much easier and less costly across Africa and has boosted researchers' hopes of developing an effective weapon against one of the world's worst killer diseases. A final trial involving thousands of children across Africa is planned for next year, if regulatory approval can be obtained.
About 500 million episodes of malaria occur every year, mostly in the developing world. The disease is caused by a parasite transmitted by the female anopheles mosquito and is the leading killer of children under the age of five in sub-Saharan Africa. In the Tanzanian trial, the vaccine reduced infection with malaria over six months by up to 65 per cent in babies under one, who are most vulnerable to disease. A total of 340 infants were included who each received three doses at eight, 12 and 16 weeks. In a separate trial involving almost 900 older children in Kenya and Tanzania, aged five to 17 months, a slightly different version of the same vaccine reduced cases of malaria requiring hospital treatment by 53 per cent. The results were presented yesterday at the annual meeting of the American Society for Tropical Medicine and Hygiene in New Orleans and published in The New England Journal of Medicine.
Read the full The Independent article here.
Settlement details:As reported by a major mainstream news source.
Forecast history %
| Yes |
| ||||
| No |
|
Question suspends in 4 years
- Activity: H$290 |
- Predictions: 4 |
Comments: 0
Suspend date: Mon 30th Dec 2013 11:59pm PST (4 years to go)
Initial likelihoods: Yes: 80%
Action history:
Changed Description Mon 8th Dec 2008 11:38pm PST by 
tisha![[Admin]](http://www.hubdub.com/images/icon_admin.gif "This user is an admin")
: show details
tisha: show details ... for infants and young children. <br/> <br/> . The vaccine, known only by ... in the Gambia and Mozambique. <.<br/> <br/> The latest trials, ... regulatory approval can be obtained. <.<br/> <br/> About 500 million ... five in sub-Saharan Africa. <br/> <br/> . In the Tanzanian trial, the ... treatment by 53 per cent. <br/> <br/> . The results were presented yesterday ... Medicine. <br/> <br/> <a href='="http://www.independent.co.uk/ ... -within-five-years-1058007.html'> <"><br/> Read the full The
Suspend date: Mon 30th Dec 2013 11:59pm PST (4 years to go) details 
Get widget!Predictions (4)
xihrhubdub
predicted No (H$20 at 20%)
dingoh
predicted No (H$20 at 20%)
predicted Yes (H$50 at 80%)Comments (0)
Stake virtual dollars on the outcomes of real news stories! Win more if you're right and climb the leaderboards Learn more...
By joining you are agreeing to our terms of service
Related News 
This news is selected automatically based on the question, its background, options and tags
This news is selected automatically based on the question, its background, options and tags
score: 10
Herald Sun 27 weeks ago
AUSTRALIAN scientists are in the final stretch of developing a vaccine which could dramatically cut deaths from the world's seventh biggest disease killer. Rheumatic Heart Disease and Acute Rheumatic Fever start out as a relatively minor bacterial throat
score: 10
Herald Sun 27 weeks ago
AUSTRALIAN scientists are in the final stretch of developing a vaccine which could dramatically cut deaths from the world's seventh biggest disease killer. Rheumatic Heart Disease and Acute Rheumatic Fever start out as a relatively minor bacterial throat
score: 10
PharmaBiz 28 weeks ago
FDA) granted priority review to the company's Biologic License Application (BLA) for Prevnar 13, Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein), which was submitted on March 31. Priority review designation is given to products that,
score: 10
Reuters 28 weeks ago
-- Candidate vaccine designed to protect against the 13 most prevalent serotypes associated with pneumococcal disease -- COLLEGEVILLE, Pa., May 7 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today
score: 10
Morningstar.com 28 weeks ago
period of 2008. The strong quarter was driven by significant growth in sales of the pentavalent children's vaccine Quinvaxem®. * Aeras and Crucell announced the start of a Phase I clinical trial in infants of the jointly developed tuberculosis
Related Tags
No comments yet
Please log in or join to add a comment